Dabigatran in Afib

In the previously published RE-LY trial, dabigatran was non-inferior to warfarin in stroke prevention in patients with afib. In this pre-specified sub-group analysis, dabigatran performed better (for preventing vascular events and mortality) than warfarin at sites with poor warfarin control (i.e. higher time to therapeutic INR). Dabigatran may be better than “non-inferior” to warfarin in “real life”, where INR control is worse than in clinical trials (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment